Adenoviral Vector Targeting via Mitigation of Liver Sequestration

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Only a few diseases can be addressed by delivering genes or vectors to a single tissue. In many cases, systemic delivery by intravenous injection will be the best approach to deliver therapeutic viruses throughout the body. Although the intravenous route is appealing, adenoviruses are bound and sequestered by an overlapping arsenal of antipathogen elements that inactivate or mistarget these therapeutics. These include interactions with natural antibodies, adaptive antibodies, blood factors, complement, blood cells, endothelial cells, Kupffer cells, macrophages, and liver hepatocytes. Many of these interactions occur by binding to the 720 copies of the hexon protein that is a multivalent patterned surface on adenovirus icosahedrons. We describe here our current understanding of interactions with the adenovirus hexon and methods to avoid loss of viruses during systemic therapy.

Original languageEnglish (US)
Title of host publicationAdenoviral Vectors for Gene Therapy: Second Edition
PublisherElsevier Inc.
Pages293-317
Number of pages25
ISBN (Print)9780128002766
DOIs
StatePublished - Apr 6 2016

Fingerprint

Viruses
Adenoviridae
Liver
Blood
Arsenals
Antibodies
Macrophages
Endothelial cells
Kupffer Cells
Genes
Tissue
Intravenous Injections
Hepatocytes
Blood Cells
Therapeutics
Endothelial Cells
Proteins

Keywords

  • Adenovirus
  • Blood clotting factors
  • Complement
  • Detargeting
  • Hepatocytes
  • Hexon
  • HPMA
  • Kupffer cells
  • Liver sinusoidal endothelial cells
  • PEG
  • Platelets
  • Red blood cells
  • Retargeting

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Barry, M. A. (2016). Adenoviral Vector Targeting via Mitigation of Liver Sequestration. In Adenoviral Vectors for Gene Therapy: Second Edition (pp. 293-317). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-800276-6.00011-5

Adenoviral Vector Targeting via Mitigation of Liver Sequestration. / Barry, Michael A.

Adenoviral Vectors for Gene Therapy: Second Edition. Elsevier Inc., 2016. p. 293-317.

Research output: Chapter in Book/Report/Conference proceedingChapter

Barry, MA 2016, Adenoviral Vector Targeting via Mitigation of Liver Sequestration. in Adenoviral Vectors for Gene Therapy: Second Edition. Elsevier Inc., pp. 293-317. https://doi.org/10.1016/B978-0-12-800276-6.00011-5
Barry MA. Adenoviral Vector Targeting via Mitigation of Liver Sequestration. In Adenoviral Vectors for Gene Therapy: Second Edition. Elsevier Inc. 2016. p. 293-317 https://doi.org/10.1016/B978-0-12-800276-6.00011-5
Barry, Michael A. / Adenoviral Vector Targeting via Mitigation of Liver Sequestration. Adenoviral Vectors for Gene Therapy: Second Edition. Elsevier Inc., 2016. pp. 293-317
@inbook{4e3b2f0d39dd460ca46b68e700407c06,
title = "Adenoviral Vector Targeting via Mitigation of Liver Sequestration",
abstract = "Only a few diseases can be addressed by delivering genes or vectors to a single tissue. In many cases, systemic delivery by intravenous injection will be the best approach to deliver therapeutic viruses throughout the body. Although the intravenous route is appealing, adenoviruses are bound and sequestered by an overlapping arsenal of antipathogen elements that inactivate or mistarget these therapeutics. These include interactions with natural antibodies, adaptive antibodies, blood factors, complement, blood cells, endothelial cells, Kupffer cells, macrophages, and liver hepatocytes. Many of these interactions occur by binding to the 720 copies of the hexon protein that is a multivalent patterned surface on adenovirus icosahedrons. We describe here our current understanding of interactions with the adenovirus hexon and methods to avoid loss of viruses during systemic therapy.",
keywords = "Adenovirus, Blood clotting factors, Complement, Detargeting, Hepatocytes, Hexon, HPMA, Kupffer cells, Liver sinusoidal endothelial cells, PEG, Platelets, Red blood cells, Retargeting",
author = "Barry, {Michael A}",
year = "2016",
month = "4",
day = "6",
doi = "10.1016/B978-0-12-800276-6.00011-5",
language = "English (US)",
isbn = "9780128002766",
pages = "293--317",
booktitle = "Adenoviral Vectors for Gene Therapy: Second Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Adenoviral Vector Targeting via Mitigation of Liver Sequestration

AU - Barry, Michael A

PY - 2016/4/6

Y1 - 2016/4/6

N2 - Only a few diseases can be addressed by delivering genes or vectors to a single tissue. In many cases, systemic delivery by intravenous injection will be the best approach to deliver therapeutic viruses throughout the body. Although the intravenous route is appealing, adenoviruses are bound and sequestered by an overlapping arsenal of antipathogen elements that inactivate or mistarget these therapeutics. These include interactions with natural antibodies, adaptive antibodies, blood factors, complement, blood cells, endothelial cells, Kupffer cells, macrophages, and liver hepatocytes. Many of these interactions occur by binding to the 720 copies of the hexon protein that is a multivalent patterned surface on adenovirus icosahedrons. We describe here our current understanding of interactions with the adenovirus hexon and methods to avoid loss of viruses during systemic therapy.

AB - Only a few diseases can be addressed by delivering genes or vectors to a single tissue. In many cases, systemic delivery by intravenous injection will be the best approach to deliver therapeutic viruses throughout the body. Although the intravenous route is appealing, adenoviruses are bound and sequestered by an overlapping arsenal of antipathogen elements that inactivate or mistarget these therapeutics. These include interactions with natural antibodies, adaptive antibodies, blood factors, complement, blood cells, endothelial cells, Kupffer cells, macrophages, and liver hepatocytes. Many of these interactions occur by binding to the 720 copies of the hexon protein that is a multivalent patterned surface on adenovirus icosahedrons. We describe here our current understanding of interactions with the adenovirus hexon and methods to avoid loss of viruses during systemic therapy.

KW - Adenovirus

KW - Blood clotting factors

KW - Complement

KW - Detargeting

KW - Hepatocytes

KW - Hexon

KW - HPMA

KW - Kupffer cells

KW - Liver sinusoidal endothelial cells

KW - PEG

KW - Platelets

KW - Red blood cells

KW - Retargeting

UR - http://www.scopus.com/inward/record.url?scp=84969667325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969667325&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-800276-6.00011-5

DO - 10.1016/B978-0-12-800276-6.00011-5

M3 - Chapter

AN - SCOPUS:84969667325

SN - 9780128002766

SP - 293

EP - 317

BT - Adenoviral Vectors for Gene Therapy: Second Edition

PB - Elsevier Inc.

ER -